Schering-Plough has announced that EMEA has accepted its Marketing Authorization Application (MAA) for a fixed-dose combination of mometasone furoate and formoterol fumarate, for the maintenance treatment of asthma
BioAlliance Pharma has reported positive preliminary results for its LIP phase III pivotal, multicenter randomised, double-blind, placebo controlled study (Lauriad Immunocompetent Patients Study). The company said that this
UCB, a Belgium-based bio pharmaceutical firm, and Immunomedics, a US-based developer of monoclonal and antibody-based products, have released top-line results from UCB’s phase IIb clinical study. The trial
Bio-Matrix (BMSN) and its majority-owned subsidiary, Entest BioMedical have finalized an agreement with Therinject for the development of a new immuno-therapeutic cancer vaccine. Reportedly, it is anticipated
Nymox has reported that NX-1207 has showed positive results when given to animals with hepatocellular carcinoma (HCC). NX-1207 is a novel drug in phase 3 development, for the
Pfizer Japan and Astellas have reached a co-promotion agreement for a combination drug of hypertension treatment and hypercholesterolemia treatment – Caduet Combination Tablets in Japan. Pursuant to the
Transcend services (Transcend) has entered into an agreement to acquire Medical Dictation Services (MDI) for $16.2m. Reportedly, the $16.2m purchase price consists of $10m in cash payable at
QRxPharma has completed its pilot study to evaluate the analgesic efficacy and safety profile of MoxDuo IR capsules in patients with moderate to severe pain following total knee
Genmab has announced positive top-line results from the phase II study of Arzerra (ofatumumab), in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP), in patients with previously untreated
MedQuist, a provider of technology-enabled clinical documentation services, has bagged a preferred vendor contract from Wellmont Health System, a provider of health care services, for enterprise medical transcription
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.